To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Expert Interview Hematologic Malignancies Recent Advances in Multiple Myeloma An Expert Interview with Shaji K Kumar Mayo Clinic, Rochester, Minnesota, US O ncology & Hematology Review (US) are delighted to introduce our new Editor-in-Chief, Shaji K Kumar, consultant in the Division of Hematology at Mayo Clinic, and Professor of Medicine in the College of Medicine, Mayo Clinic, Rochester, Minnesota, US. In a recent interview, Dr Kumar discussed the latest advances in multiple myeloma, one of his major research interests. Keywords Multiple myeloma, disease progression, immunotherapy Disclosure: Shaji K Kumar has nothing to disclose in relation to this article. This is an expert interview, and as such has not undergone the journal's standard peer review process. Acknowledgments: Medical writing assistance was provided by Katrina Mountfort, Freelance Medical Writer, supported by Touch Medical Media. Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. Received: February 27, 2017 Published Online: April 14, 2017 Citation: Oncology & Hematology Review, 2017;13(1):13–4 Corresponding Author: Shaji K Kumar, MD, Professor of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, US. E: [email protected] TOU CH MED ICA L MEDIA Oncology and Hematology Review (US) would like to welcome our new Editor-in-Chief, Shaji K Kumar, MD. Dr Kumar is a consultant in the Division of Hematology at Mayo Clinic, and Professor of Medicine in the College of Medicine, Mayo Clinic, Rochester, Minnesota, US. He is currently the chair of the NCCN panel on multiple myeloma and is the co-chair of the NCI multiple myeloma steering committee. A significant component of Dr Kumar’s research efforts are directed toward studying novel treatment approaches in myeloma through well-designed clinical trials. He is principal investigator on multiple phase I, II, and III trials for plasma cell malignancies, which include a combination of Mayo investigator-initiated trials, industry-sponsored trials, and cooperative group trials. From a translational research standpoint, his laboratory has focused on development of new agents for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar receives ongoing support for research from the National Institutes of Health and the National Cancer Institute. He is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, American Association for Clinical Research, American Society for Blood and Marrow Transplantation, American Medical Association, Association of Physicians of India, and the European Hematology Association. His work has appeared in peer reviewed journals such as Lancet Oncology, Journal of Clinical Oncology, Blood Cancer Journal, Leukemia, American Journal of Hematology, Mayo Clinic Proceedings, Blood, and European Journal of Hematology. He received his medical degree from the All India Institute of Medical Sciences, New Delhi, India. He completed an internship there, followed by a clinical residency in internal medicine and a senior residency in medical oncology. Dr Kumar subsequently completed a residency in internal medicine and a fellowship in hematology/oncology at Mayo Graduate School of Medicine. He then spent time as a research associate and Mayo Foundation Scholar in multiple myeloma at Dana-Farber Cancer Institute-Harvard Cancer Center. 13